Journals / Çukurova Üniversitesi Tıp Fakültesi Dergisi / 2013 / Cilt: 38 - Sayı: 1

Progesteron İnsan miyometrial kontraksiyonlarını membran reseptörleri aracılığı ile inhibe etmektedir

Progesterone inhibits human myometrial contractions by its action on membrane receptors

Pages
92–102
Publication Date
2022-10-10
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusions: P4 rapidly inhibits myometrial contractility by nongenomic mechanisms through action on mPR but not via cAMP, cGMP, or NO

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Purpose: The mechanisms for myometrial inhibition are still being investigated.
📊
Key Findings & Data:The aim of this article is to examine mechanisms of progesterone (P4) inhibition of uterine contractility.
💡
Conclusion & Impact:Conclusions: P4 rapidly inhibits myometrial contractility by nongenomic mechanisms through action on mPR but not via cAMP, cGMP, or NO
🔬Design:Research Article
📍Scope:2010-2011 Verileri
⚙️Variables:Domain Parameters

Abstract

Purpose: The mechanisms for myometrial inhibition are still being investigated. The aim of this article is to examine mechanisms of progesterone (P4) inhibition of uterine contractility. Methods: Prospective study Tertiary care center at St. Joseph s Hospital and at Maricopa Hospital, Phoenix, AZ and research center in Arizona, USA. During 2010-2011 24 women were given birth by cesarean section. Uterine tissues from women (n=24) at term were suspended in organ chambers and exposed to various agents. Contractility was recorded and compared before and after addition of agents. Tissues were treated with P4 alone, a progestin (R5020) with low affinity to the progesterone membrane receptor (mPR), or a non-sex steroid (cholesterol). Other tissues were pretreated with inhibitors of adenylate cyclase (SQ 22536), phosphodiesterase (rolipram), nitric oxide (NO) synthases (L-NAME) or a nuclear P4 receptor antagonist (mifepristone, MIF), followed by P4. Data were analyzed by ANOVA. Results: P4 (P0.05) inhibitory effects. P4 inhibition is not blocked by MIF, SQ, ODQ, rolipram or L-NAME (P>0.05). Conclusions: P4 rapidly inhibits myometrial contractility by nongenomic mechanisms through action on mPR but not via cAMP, cGMP, or NO

Özet

Amaç: Miyometrialinhibisyon mekanizmaları halen araştırılmaktadır. Bu çalışmanın amacı progesteronun (P4) uterin kontraktilitesi üzerine olan inhibisyon mekanizmasını incelemektir. Yöntem: Prospektif çalışma St. Joseph Hastanesi Üçüncü Basamak Tedavi Hizmetleri Merkezi ve Maricopa Hastanesi, Phoenix; AZ ile Arizona Araştırma Merkezi, ABD de gerçekleştirildi. 2010-2011 yılları sırasında 24 kadın sezaryan operasyonla doğum yaptı. Doğum esnasında kadınlardan (n=24) alınan uterin dokuları organ banyolarında bekletilerek çeşitli ajanlara maruz bırakıldı. Kontraktilite, ajanların eklenmesinden önce ve sonra kayıt edildi ve karşılaştırıldı. Dokular ya yalnız P4 ile, ya progesteron membran reseptörüne (mPR) düşük afinitesi olan progestin (R5020) ile veya bir non-seks steroidi (kolesterol) ile muamele edildi. Diğer dokular ise adenilat siklaz inhibitörü (SQ22536), fosfodiesteraz inhibitörü (rolipram), nitrik oksit (NO) sentaz inhibitörü (L-NAME) veya nükleer P4 reseptör antagonistine (mifepristone, MIF) maruz bırakıldıktan sonra P4 ile muamele edildi. Veriler ANOVA ile analiz edildi. Bulgular: Progesteron (p0.05) çok az inhibe edici etkiye sahipti. Progesteron inhibisyonu MIF, SQ, ODQ, rolipram veya L-NAME (p>0.05) ile bloke edilemedi. Sonuç: Progesteron miyometrial kontraksiyonu genomik olmayan mekanizmalarla; cAMP, cGMP veya NO ile ilişkili olmadan, sadece mPR aracılığı ile hızlı bir şekilde inhibe etmektedir.

🔖

Cite This Article

GÖKDENİZ, R., OVAYOLU, A., GARFİELD, E. R. (2022). Progesteron İnsan miyometrial kontraksiyonlarını membran reseptörleri aracılığı ile inhibe etmektedir. Çukurova Üniversitesi Tıp Fakültesi Dergisi, Cilt: 38 - Sayı: 1, 92–102. https://ajindex.com/articles/485991

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Fsapo A. Force of labour. In: Iffy L, Kaminetzky HA, editors. Principles and Practice of Obstetrics and Perinatology. John Wiley and Sons, Inc. 1981; 761-799
  2. Chwalisz K, Hegele-Hartung C, Schulz R, Shi SQ, Louton PT. Progesterone control of cervical ripening - experimental studies with the progesterone antagonists onapristone, lilopristone and mifepristone. In: Leppert P, Woessner F, editors. The Extracellular Matrix of the Uterus, Cervix and Fetal Membranes: Synthesis, Degradation and Hormonal Regulation. Perinatology Press. 1991; 119-131
  3. Chwalisz K, Garfield RE. Regulation of the uterus and cervix during pregnancy and labor. Ann NY Acad Sci. 1997; 828: 238-53
  4. Hegele-Hartung C, Chwalisz K, Beier HM, Elger W. Ripening of the uterine cervix of the guinea-pig after treatment with the progesterone antagonist Onapristone (Zk-98.299) - an electron-microscopic study. Hum Reprod. 1989; 4: 369-77
  5. Johnson JW, Austin KL, Jones GS, Davis GH, and King TM. Efficacy of 17 alpha-hydroxyprogesterone caproate in the prevention of premature labor. N Engl J Med. 1975; 293: 675-80
  6. Yemini M, Borenstein R, Dreazen E. Prevention of premature labor by 17 alpha-hydroxyprogesterone caproate in the prevention of premature labor. Am J Obstet Gynaecol. 1985; 151: 574-77
  7. Harrikainen-Sorri AL, Kauppila, A, Tuimala, R. Inefficacy of 17 alpha-hydroxyprogesterone caproate in the prevention of prematurity in twin pregnancy. Obstet Gynaecol. 1980; 56: 692-95
  8. Keirse MJ. Progestogen administration in pregnancy may prevent preterm delivery. Br J Obstet Gynaecol. 1990; 97: 149-54
  9. Meis PJ, Klebanoff M, Thom E, Dombrowski MP, Sibai B, Moawad AH, et al. Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate. N Eng J Med. 2003; 348: 2379-85. 10. da Fonseca EB, Bittar RE, Carvalho MHB, Zugaib M. Prophylactic administration of progesterone by vaginal suppository to reduce the incidence of spontaneous preterm birth in women at increased risk: a randomized placebo-controlled double-blind study. Am J Obstet Gynaecol. 2003; 188: 419-24
  10. Barnafi L, Larraguibel R. The in vitro effect of progesterone and oestrogens on thespontaneous and oxytocin-induced activity of the human myometrium. Acta Endocrinol. 1974; 76: 172-7
  11. Batra S, Bengtsson B. Effects of diethylstilboestrol and ovarian steroids on the contractile responses and calcium movements in rat uterine smooth muscle. J Physiol. 1978; 276: 329-42
  12. Fu X, Rezapour M, Lofgren M, Ulmst